Thank you, Eric, and thank you, Anders. I will continue today's session by summarizing the second quarter of 2026 and also describe how BICO Group AB serves the world's leading pharma and biotech companies with solutions that transform how labs operate, innovate, and solve our customer challenges. Following that, Ewa will then present the group's financial performance. I will also comment on our R&D pipeline and our ongoing product development efforts. Additionally, I will highlight some recent product launches. The session will then conclude.
And before we open up our Q&A about the financial results. In the quarter, we saw continued good sales momentum navigating a dynamic market still affected by geopolitical uncertainty. But we are gaining confidence in a gradual market recovery. Although the academic end markets remain soft due to reduced funding. Sales amounted to 336 million SEK, an organic growth in local currencies of 7%, mainly derived from continued strong benchtop instrument and consumable sales, while still experiencing challenges in the project-based business due to continued currency headwinds. Our total growth was 4% in the second quarter. We also see an improved profitability in the quarter as commercial and operational excellence activities are paying off, decreasing our overall costs, resulting in an adjusted EBITDA of 20 million SEK or an adjusted EBITDA margin of 6%. Cash flow from operating activities totaled -53 million SEK, which is mainly stemming from changes in net working capital after the period ended. One of our business units successfully signed long-term supply and license agreements as a prolongation of its ongoing business with one of its current customers, and the agreements have a combined contracted value of approximately €50 million over a ten-year term. All numbers presented are in million SEK unless otherwise stated. Before Ewa provides more details on our financial performance, I will present how BICO serves the world's leading pharma and biotech companies with solutions that transform how labs operate and innovate, which is what our mission is about. BICO supports customers to advance science so that therapies can reach patients faster. Our solutions, with predominantly benchtop instruments, enable smarter, faster, and more efficient labs in which we see an underlying strong demand. Pharma and Biotech companies all face the same fundamental challenge: long and costly development cycles for new therapies, and the development of a new therapy often takes more than ten years and costs between 2 and 4 billion USD, with the probability of approval after phase one at just 10%. And to overcome this, our pharma and biotech customers are investing heavily in automation and AI to increase efficiency, speed and quality, to bring innovations to market faster and at lower cost. AI accelerates discovery, and then the wet labs become the new bottleneck. Generative models and predictive biology dramatically speed up hypothesis generation. Wet lab automation and validation. Wet lab automation and validation remains the hard constraint. In fact, more AI-driven candidates mean more experiments, not fewer. Intensifying pressure on lab throughput, system uptime, and data reproducibility. This means that wet labs have become more critical than obsolete. AI breakthroughs have made wet labs even more central to R&D, and the lab is now a biological compute cluster, validating AI predictions.
So high-throughput automation and trusted data become mission-critical. Customers using BICO lab automation solutions consistently report measurable gains in productivity and reliability, including reduced hands-on time, faster turnaround time, and higher instrument utilization. So to summarize, BICO leads the way in solving the challenges in life science with speed, accuracy, and efficiency. All in all, our customers can run their processes faster, improve the quality of the data, and ultimately make better decisions.
And I will now hand over to Ewa Linsäter to present the results for the second quarter.